Please login to the form below

Not currently logged in
Email:
Password:

Greenleaf Health appoints drug and biological products principal

Dr John Jenkins joins the FDA regulatory consulting firm

Washington, US-based Greenleaf Health has appointed Dr John Jenkins as principal for drug and biological products.

Dr Jenkins brings over 25 years of experience from the US Food and Drug Administration (FDA) to the regulatory consulting firm, and is set to oversee its clients' drug development programmes through regulatory submission and post-approval requirements.

Most recently, he served as director of the office of new drugs within the FDA's Center for Drug Evaluation and Research. He previously held several leadership positions at the regulatory body, including director of the office of drug evaluation and director of the division of pulmonary drug products.

Patrick Ronan, chief executive of Greenleaf Health, said: “No one is more qualified than John to provide our clients strategic and technical guidance on FDA's regulatory process for drug and biological product development.

“Our experts at Greenleaf, who have a combined total of more than 200 years of FDA experience, help our clients navigate complex regulatory challenges. John's knowledge and experience in this area are unrivaled, and he makes a great addition to our team.”

20th February 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics